Epperly Melissa B, 4

What Happened Melissa Epperly, a director of Nautilus Biotechnology (NAUT), received a grant of a derivative equity award covering 45,000 shares on June 18, 2026. The Form 4 reports an acquisition at $0.00 per share (total reported value $0.00) and classifies the transaction as a derivative award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed four days after the transaction; exceeds the typical 2-business-day Form 4 window).
• Type: Award/Grant (derivative) — 45,000 shares reported at $0.00 per share (reported total $0).
• Shares owned after the transaction: Not disclosed in the provided filing.
• Footnote: Vesting is subject to the reporting person’s continuous status as a “Service Provider” under Nautilus’s 2021 Equity Incentive Plan. Per the footnote, one‑twelfth (1/12) of the shares subject to the option vest monthly following the grant date.
• No indication this was a cashless exercise or an open‑market trade.

Context This was a compensation-style derivative award that vests monthly over a one‑year schedule (per the footnote). Such grants are routine for executives and directors as part of long-term incentive programs and do not by themselves indicate insider buying or selling sentiment. Purchases tend to be more directly informative about an insider’s view of the stock; this filing documents a standard equity grant with a multi-month vesting schedule.